§ 314.97. Supplements and other changes to an approved ANDA.
141 words·~1 min read·
/us/cfr/t21/s§ 314.97·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)General requirements. The applicant must comply with the requirements of §§ 314.70 and 314.71 regarding the submission of supplemental ANDAs and other changes to an approved ANDA.
(b)Different listed drug. An applicant may not supplement an ANDA to seek approval of a drug referring to a listed drug that is different from the current reference listed drug identified in the ANDA. This paragraph
(b)applies if changes are proposed in a supplement to the ANDA such that the proposed product is a pharmaceutical equivalent to a different listed drug than the reference listed drug identified in the ANDA. A change of reference listed drug must be submitted in a new ANDA. However, notwithstanding the limitation described in this paragraph (b), an applicant may supplement the ANDA to seek approval of a different strength. [81 FR 69653, Oct. 6, 2016]
Connections11 cite this
Cited by 11 sections
register
- NoticesNotice
- Presidential DocumentsIntroduction to the Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions
- Presidential DocumentsIntroduction to the Unified Agenda of Federal Regulatory and Deregulatory Actions
- Proposed RulesProposed rule
- NoticesNotice of availability
- NoticesNotice
- Proposed RulesProposed rule
- NoticesNotice of availability
- NoticesIntroduction to the Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions
- Proposed RulesProposed rule
- Proposed RulesProposed rule
Citation graph
cites case law
§ 314.97
Supplements and other changes to an approved ANDA.
Fed. Reg.×11
Cites 0Cited by 11 across 1 source